Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration-Reference-Cited by-同舟云学术

Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

Published:2015-08-12 Issue:10 Volume:4 Page:e1022301
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Datta Jashodeep¹^ORCID,Rosemblit Cinthia¹,Berk Erik¹^ORCID,Showalter Lori²,Namjoshi Prachi²,Mick Rosemarie³,Lee Kathreen P¹,Brod Andrew M¹,Yang Rachel L⁴,Kelz Rachel R¹,Fitzpatrick Elizabeth¹,Hoyt Clifford⁵^ORCID,Feldman Michael D⁶,Zhang Paul J⁶^ORCID,Xu Shuwen¹,Koski Gary K²,Czerniecki Brian J¹⁷

Affiliation:

1. Department of Surgery; University Pennsylvania Perelman School of Medicine; Philadelphia, PA USA

2. Department of Biological Sciences; Kent State University; Kent, OH USA

3. Department of Epidemiology and Biostatistics; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA USA

4. Department of Surgery; Stanford University Hospital and Clinics; Palo Alto, CA USA

5. Life Sciences & Technology; PerkinElmer Inc.; Hopkinton, MA USA

6. Department of Pathology; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA USA

7. Rena Rowen Breast Center; Hospital of the University of Pennsylvania; Philadelphia, PA USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1022301

Reference38 articles.

1. Global cancer statistics

2. Molecular portraits of human breast tumours

3. HER2/neu in the management of invasive breast cancer

4. Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression

5. Pathological features and prognosis of different molecular subtypes of breast cancer

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer;Frontiers in Immunology;2024-02-29

2. Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development;Molecular Aspects of Medicine;2024-02

3. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08

4. Update on Management of Ductal Carcinoma in Situ;Clinical Breast Cancer;2023-12

5. Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy—An Observational Study;International Journal of Molecular Sciences;2023-10-31